Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)

December 8, 2021 updated by: Teva Branded Pharmaceutical Products R&D, Inc.

A Phase 3, Multicenter, Randomized, Open-Label, Comparator-Controlled Study to Assess Safety and Tolerability of Weekly TV-1106 Compared to Daily rhGH (Genotropin(R)) in Adults With Growth Hormone-Deficiency

This study assesses the safety and tolerability of weekly TV-1106 compared to daily rhGH in adults with GHD who have previously been treated with rhGH.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

34

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
      • Linz, Austria, A-4020
        • Teva Investigational Site 33035
  • Czechia
      • Brno, Czechia, 656 91
        • Teva Investigational Site 54118
      • Moravskoslezsky, Czechia, 708 00
        • Teva Investigational Site 54119
      • Plzensky, Czechia, 304 60
        • Teva Investigational Site 54116
  • Greece
      • Athens, Greece, 11527
        • Teva Investigational Site 63059
      • Chaidari, Greece, 12462
        • Teva Investigational Site 63058
      • Ioannina, Greece
        • Teva Investigational Site 63060
  • Hungary
      • Budapest, Hungary, 1062
        • Teva Investigational Site 51202
      • Budapest, Hungary, 1088
        • Teva Investigational Site 51206
      • Debrecen, Hungary, 4032
        • Teva Investigational Site 51205
      • Pecs, Hungary, 7624
        • Teva Investigational Site 51204
      • Szeged, Hungary, 6725
        • Teva Investigational Site 51208
      • Szolnok, Hungary, 5000
        • Teva Investigational Site 51207
  • Italy
      • Brescia, Italy, 25018
        • Teva Investigational Site 30129
  • Slovakia
      • Lubochna, Slovakia, 034 91
        • Teva Investigational Site 62041
  • Spain
      • Badalona, Spain, 08916
        • Teva Investigational Site 31129
      • Cordoba, Spain, 14004
        • Teva Investigational Site 31121
      • Madrid, Spain, 28805
        • Teva Investigational Site 31125
  • United States
    • California
      • Artesia, California, United States, 90701
        • Teva Investigational Site 13137
      • Fountain Valley, California, United States, 33155-6541
        • Teva Investigational Site 13166
      • Lakewood, California, United States, 90712
        • Teva Investigational Site 13165
    • Colorado
      • Denver, Colorado, United States, 80209
        • Teva Investigational Site 13155
    • Delaware
      • Newark, Delaware, United States, 19713
        • Teva Investigational Site 13158
    • Florida
      • Fort Lauderdale, Florida, United States, 33312
        • Teva Investigational Site 13162
      • Homestead, Florida, United States, 33030
        • Teva Investigational Site 13136
      • Miami, Florida, United States, 33126
        • Teva Investigational Site 13138
      • Miami, Florida, United States, 33130
        • Teva Investigational Site 13152
      • Miami, Florida, United States, 33145
        • Teva Investigational Site 13161
      • Miami, Florida, United States, 33155-6541
        • Teva Investigational Site 13500
      • Miami, Florida, United States, 33175
        • Teva Investigational Site 13503
      • Miami Lakes, Florida, United States, 33016
        • Teva Investigational Site 13148
      • Pembroke Pines, Florida, United States, 33024
        • Teva Investigational Site 13134
      • West Palm Beach, Florida, United States, 33401
        • Teva Investigational Site 13129
    • Michigan
      • Detroit, Michigan, United States, 48202
        • Teva Investigational Site 13135
    • Nevada
      • Henderson, Nevada, United States, 89052
        • Teva Investigational Site 13146
      • Las Vegas, Nevada, United States, 89148
        • Teva Investigational Site 13147
    • New York
      • Brooklyn, New York, United States, 11235
        • Teva Investigational Site 13143
      • New York, New York, United States, 10016
        • Teva Investigational Site 13502
      • New York, New York, United States, 10032
        • Teva Investigational Site 13140
    • North Carolina
      • Asheville, North Carolina, United States, 28803
        • Teva Investigational Site 13128
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15212
        • Teva Investigational Site 13142
    • Texas
      • Arlington, Texas, United States, 76014
        • Teva Investigational Site 13144
      • Dallas, Texas, United States, 75218
        • Teva Investigational Site 13163
      • Houston, Texas, United States, 77079
        • Teva Investigational Site 13130
      • Houston, Texas, United States, 77084
        • Teva Investigational Site 13141
      • Houston, Texas, United States, 77090
        • Teva Investigational Site 13154
    • Virginia
      • Norfolk, Virginia, United States, 23507
        • Teva Investigational Site 13159
    • Washington
      • Federal Way, Washington, United States, 98003
        • Teva Investigational Site 13504
      • Seattle, Washington, United States, 98122
        • Teva Investigational Site 13164
      • Tacoma, Washington, United States, 98405
        • Teva Investigational Site 13157

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • males and females 18 years of age or over
  • diagnosis of adult GHD for at least 6 months, or patients who have hypopituitarism from surgical resection
  • treated with a stable dose of daily rhGH for at least 3 months prior to screening

  • stable, adequate doses of replacement hormones (adrenal, thyroid, estrogen, testosterone, vasopressin) for at least 3 months prior to screening

    • Other criteria apply, please contact the investigator for more information

Exclusion Criteria:

  • patients with acute or chronic conditions or diseases that could confound results of the study or put the patient at undue risk as determined by the investigator
  • Presence of contraindications to rhGH treatment
  • patients who have participated in another clinical trial with a new chemical/biological entity within 3 months of screening
  • patients with known active malignancy (excluding surgically removed basal cell carcinoma or carcinoma in situ of cervix) d. patients with a previously treated pituitary tumor with evidence of tumor progression in the past year
  • patients with a new diagnosis of pituitary adenoma or other intracranial tumor within 12 months of screening
  • presence of Prader-Willi syndrome, Turner's syndrome, untreated adrenal insufficiency, active acromegaly in the past 5 years, or active Cushing's syndrome in the past year.
  • patients with type 1 diabetes mellitus oror poorly controlled type 2 diabetes mellitus as indicated by a glycated hemoglobin (HbA1c) ≥8%

  • patients using weight reducing agents or appetite suppressants

    • Other criteria apply, please contact the investigator for more information

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: TV-1106
TV-1106 to be injected once weekly.
Drug: TV-1106
The volume necessary to provide the required weekly dose will be calculated by the investigator; dose will be adjusted for IGF-I in the normal range.
Other Names:
  • rhGH
Active Comparator: dGH
dGH to be given as daily injections.
Drug: dGH
The dose levels of dGH will be the same as the stable rhGH dose taken prior to the study.
Other Names:
  • Somatropin
  • rhGH

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of participants with adverse events
Time Frame: 48 weeks
Safety of TV-1106 compared to reference drug
48 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
Change from baseline in Insulin-like Growth Factor 1 Standard Deviation Score
Time Frame: Baseline, Weeks: 4, 8, 12, 16, 24, 36, 48
Baseline, Weeks: 4, 8, 12, 16, 24, 36, 48

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 30, 2015

Primary Completion (Actual)

February 29, 2016

Study Completion (Actual)

April 30, 2016

Study Registration Dates

First Submitted

March 30, 2015

First Submitted That Met QC Criteria

April 1, 2015

First Posted (Estimate)

April 7, 2015

Study Record Updates

Last Update Posted (Actual)

December 10, 2021

Last Update Submitted That Met QC Criteria

December 8, 2021

Last Verified

December 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TV1106-IMM-30022

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Growth Hormone Deficiency

Clinical Trials on TV-1106

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe